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Background: Renal dysfunction is one of the most powerful prognostic factors for clinical outcomes in heart failure and often impedes adequate 
decongestion and utilization of evidence-based therapies. To date, no successful therapeutic strategies to improve renal function or outcomes in 
these patients have been identified. Digitalis glycosides are known to improve hemodynamics and also have direct beneficial effects on kidney 
function. The primary objective of this study was to determine if randomization to digoxin is associated with improvement in renal function (IRF) and 
to evaluate if these potential changes in renal function interact with long-term outcomes.
Methods: Subjects in the Digitalis Intervention Group trial limited dataset with creatinine levels available at baseline and 12 months (determined 
in a random sample, n=980) were studied. IRF was defined as a ≥ 20% increase in glomerular filtration rate (GFR) from randomization to 12 months.
Results: IRF occurred in 15.5% of the population (mean improvement in GFR 34.5 ± 15.4%) and was significantly more common in patients 
randomized to digoxin (OR=1.5, p=0.02). This association persisted after adjusting for baseline GFR (OR=1.5, p=0.03) and parameters associated 
with IRF (OR=1.6, p=0.02). Amongst patients without IRF, the incidence of death or hospitalization was similar between the placebo and digoxin 
groups (adjusted HR=0.96, 95% CI 0.8-1.2, p=0.67). However, in patients with IRF, randomization to digoxin was associated with a substantially 
reduced incidence of death or hospitalization (adjusted HR=0.49, 95% CI 0.3-0.8, p=0.006, p interaction=0.026). Similar trends were noted for the 
individual endpoints of death (p interaction=0.06) and hospitalization (p interaction=0.05).
Conclusions: In patients with chronic heart failure, randomization to digoxin is associated with a significantly greater incidence of IRF. Patients 
experiencing IRF appeared to derive particular benefit from randomization to digoxin as the reduction in death or hospitalization was primarily 
restricted to these patients. Further research is warranted to evaluate the potential value of digoxin in patients with cardio-renal dysfunction.
